Glioblastoma multiforme of the optic chiasm: A rare case of common pathology

Kirill A. Lyapichev, Amade Bregy¹, Adrienne Cassel², Chelsea Handfield², Jose Velazquez-Vega, Matthew D. Kay³, Gregory Basil², Ricardo J. Komotar²

Department of Pathology and Laboratory Medicine, Miller School of Medicine, University of Miami, Miami, FL, ¹Departments of Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, ²Neurological Surgery, Miller School of Medicine, University of Miami, Miami, ³Aventura, Florida, USA

E-mail: *Kirill A. Lyapichev - kirill.lyapichev@jhsmiami.org; Amade Bregy - Abregy@ubms.com; Adrienne Cassel - acassel@andrew.cmu.edu; Chelsea Handfield - chelsea.handfield@yale.edu; Jose Velazquez-Vega - jevelaz@emory.edu; Matthew D. Kay - chinacat72@aol.com; Gregory Basil - gregory.basil@gmail.com; Ricardo J. Komotar - RKomotar@med.miami.edu
*Corresponding author

Received: 16 May 16   Accepted: 24 May 16  Published: 07 July 16

Abstract

Background: Malignant optic and chiasmatic gliomas are extremely rare, and are classified pathologically as anaplastic astrocytoma or glioblastoma multiforme (GBM). Approximately 40 cases of optic GBM in adults have been reported in the literature, and only five of them were described to originate from the optic chiasm.

Case Description: An 82-year-old male patient with a past medical history of diabetes mellitus type 2, melanoma, and bladder cancer presented with gradual vision loss of the left eye in a period of 1 month. After neuro-ophthalmological examination, the decision of thither magnetic resonance imaging (MRI) studies was made. It showed a contrast enhancing mass in the region of the optic chiasm. In this case, imaging study was not enough to establish an accurate diagnosis and a left pterional craniotomy for biopsy and resection of the optic chiasmal mass was performed. After histological evaluation of the mass tissue, the diagnosis of GBM was made. Taking into account the patient's poor condition and unfavorable prognosis he was moved to inpatient hospice. The patient deceased within 2 months after surgery.

Conclusion: Chiasmal GBM is an extremely rare condition where a biopsy is necessary for accurate diagnosis and optimal treatment. Differential diagnosis for such lesions can be very difficult and include demyelinating optic neuritis and non-demyelinating inflammatory optic neuropathy (e.g., sarcoid), vascular lesions (e.g., cavernoma), compressive lesions of the optic apparatus, metastatic malignancy, and primary tumors of the anterior optic pathway. The role of chemotherapy and radiotherapy including novel stereotaxic radiosurgery methods is still unclear and will need to be evaluated.

Key Words: Brain tumor, glioblastoma, glioma
INTRODUCTION

Optic nerve gliomas represent approximately 2% of all brain tumors. These tumors are categorized into benign optic gliomas (pilocytic astrocytomas, neurofibromatosis type-1 (NF-1) associated low-grade astrocytomas) that typically occur in the childhood and malignant optic gliomas which occur in adulthood. Malignant optic and chiasmatic gliomas are extremely rare and are classified pathologically as anaplastic astrocytoma or glioblastoma multiforme (GBM). Approximately 40 cases of optic GBM in adults have been reported in the literature, and only five of them were described to originate from the optic chiasm. We report a very rare case of GBM arising from the optic chiasm.

CASE PRESENTATION

An 82-year-old man with an extensive medical history including chronic obstructive pulmonary disease, type 2 diabetes, coronary artery disease, history of melanoma, and previously treated bladder cancer presented with 1 month of rapid onset visual loss in the left eye. It manifested initially as a blurry vision, which progressed to severe loss of vision in the left eye. Neuro-ophtalmological examination showed a left relative afferent pupillary defect, which was suggestive of either an optic neuropathy or diffuse retinal pathology. Formal visual field testing demonstrated severe generalized depression in the left eye and a superotemporal quadrant defect in the right eye indicating pathology affecting the left optic nerve and chiasm. Subsequent magnetic resonance imaging (MRI) of the brain confirmed a contrast enhancing mass in the region of the left-side of the optic chiasm extending from the suprasellar cistern into the left optic nerve [Figure 1].

The differential diagnosis for tumors affecting the anterior visual pathway is myriad because a vast majority (84%) of patients present with visual impairment and no other ophthalmologic or neurologic symptoms. Considerations should include demyelinating optic neuritis and non-demyelinating inflammatory optic neuropathy (e.g., sarcoid), vascular lesions (e.g., cavernoma), compressive lesions of the optic apparatus, metastatic infiltration particularly in the setting of prior known systemic malignancy as in our case with a history of metastatic melanoma, and primary tumors of the anterior optic pathway.

Given the patient’s visual loss and the uncertain etiology of the lesion, a left pterional craniotomy for biopsy and resection of the optic chiasmal mass was performed.

On gross pathology, the tumor was a light-tan, irregularly-shaped soft tissue fragment measuring 0.8 × 0.3 × 0.2 cm in aggregate. On histological evaluation, the tumor was composed of glial cells with pleomorphic nuclei and areas of vascular proliferation and necrosis. Immunohistochecmy was positive for glial fibrillary acidic protein (GFAP) and p53 and showed a Ki 67 proliferation index of ~10% [Figure 2]. At the same time, the cells were negative for keratin. These results supported the diagnosis of GBM, WHO grade IV, based on the four diagnostic criteria for malignant optic nerve glioma.

Figure 1: Preoperative magnetic resonance imaging: Axial T1-weighted image with contrast demonstrating an enhancing lesion of the left pre-chiasmatic optic nerve and chiasm

Figure 2: A highly cellular astrocytic tumor is seen with marked microvascular proliferation (a), mitotic activity (b) and areas of necrosis (c). The tumor was strongly immunoreactive to glial fibrillary acidic protein immunohistochemistry (d) and the tumor nuclei were positive for p53 (e). The Ki-67 proliferation index was estimated to be approximately 10% (f)
namely, (1) necrosis, (2) vascular proliferation, (3) nuclear pleomorphism, and (4) mitoses (5).

Postoperatively, the patient felt fine and did not show any neurological impairment. No postoperative radiation or chemotherapy was administered; however, 6 days post-discharge he started to show confusion, lethargy, and unsteady gait, and was readmitted to the hospital. A lumbar puncture (LP) was performed to rule out any infectious etiology. The patient’s condition and treatment options were discussed and decision on transferring him to inpatient hospice was made. The patient deceased within 2 months after surgery.

**DISCUSSION**

Since the optic GBM infiltrates extensively and grows rapidly, the prognosis is unfavorable. Reported survival ranges from 6–14 months after diagnosis. Dinh et al. published a case of chiasmatic GBM where the patient survived 14 months after onset of the symptoms, which is the longest survival of such patients in the literature. 

Hartel et al. compiled a review of 30 cases of malignant optic nerve gliomas and reported a mean presenting age of patients with optic GBM of 52.9 years and a mean survival rate of 8 months. The mean survival rate in patients with optic glioma is shorter when compared to GBM in other locations of the brain demonstrating mean survival rate of 14.6 months.

As generally known for GBM, optic nerve GBM also shows a slight preference for males (male to female ratio is 1.38:1) and cases are reported from 22 years old to 79 years old patients. Standard treatment of GBM in most cases includes combined chemoradiation therapy. There are some alternative medical approaches specifically for optic GBM, such as medically induced hypothyroidism with carboplatin, which was seen in the Ashur-Fabian et al. study, however, none of these therapies have become standard treatment.

Although glioblastoma is a histopathologic diagnosis, novel molecular studies using the cancer genome atlas (TCGA) have identified multiple tumor subtypes providing us much more than just diagnostic information. Identification of gene mutations or amplifications/deletions such as of genes like MGMT, IDH1/IDH2, EGFR, NFKB1A, PTEN, PI3K, mTOR, to mention only a few, has significant therapeutic implications because many novel drugs specifically target certain mutated cancer cells. Examples are the multiple phase 1 clinical trials focusing on IDH-1 mutations or the O6-methylguanine-DNA methyltransferase (MGMT) promoter region hypermethylation status in gliomas and their susceptibility to alkylating chemotherapy. This knowledge of tumor composition on a molecular level will ultimately help to provide optimal patient-targeted therapy and provide us the deeper understanding of the tumor etiology to give us an opportunity to treat this deadly disease.

**CONCLUSION**

Our case represents a GBM that originated in the chiasm and then infiltrated into left optic nerve with subsequent vision impairment. There were no other lesions arising from secondary structures. Differential diagnosis for such lesions can be very difficult and biopsy may be necessary for diagnosis and optimal treatment. The role of chemotherapy and radiotherapy including novel stereotactic radiosurgery methods is still unclear and will need to be evaluated.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Alvord EC Jr., Lofton S. Gliomas of the optic nerve or chiasm. Outcome by patients’ age, tumor site, and treatment. J Neurosurg 1988;68:85-98.
2. Ashur-Fabian O, Blumenthal DT, Bakon M, Nass D, Davis PJ, Hercbergs A. Long-term response in high-grade optic glioma treated with medically induced hypothyroidism and carboplatin: A case report and review of the literature. Anticancer Drugs 2013;24:315-23.
3. Caignard A, Faguer R, Mercier P, Mené P, Milea D. Optic nerve and visual pathways primary glioblastoma treated with radiotherapy and temozolomide chemotherapy. Eur J Ophthalmol 2014;24:637-40.
4. Darefsky AS, Dubrow R. International variation in the incidence of adult primary malignant neoplasms of the brain and central nervous system. Cancer Causes Control 2009;20:1593-1604.
5. Dimitrov L, Hong CS, Yang C, Zhuang Z, Heiss JD. New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma. Int J Med Sci 2015;12:201-13.
6. Dinh TT, Wang YY, Rosendal JY, Cherny M. Glioblastoma of the optic chiasm. J Clin Neurosci 2007;14:500-5.
7. Hartel PH, Rosen C, Larzo C, Nestor S. Malignant optic nerve glioma (glioblastoma multiforme): A case report and literature review. W J Med J 2006;102:29-31.
8. Lalezari S, Chou AP, Tran A, Solis OE, Khanlou N, Chen W, et al. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro Oncol 2013;15:370-81.
9. Matloob S, Fan J, Danesh-Meyer HV. Multifocal malignant optic glioma of adulthood presenting as acute anterior optic neuropathy. J Clin Neurosci 2011;18:974-7.
10. Reithmeyer T, Graf E, Piroth T, Trippel M, Pinkser MO, Nikkhah G. BCNU for recurrent glioblastoma multiforme: Efficacy, toxicity and prognostic factors. BMC Cancer 2010;10:30.
11. Veliz I, Loo Y, Castillo O, Karachaliou N, Ngo O, Rosell R. Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future? Ann Transl Med 2015;3:7.
12. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and MEF2C. Cancer Cell 2010;17:98-110.